

## Conjunctival Transcriptome in Scarring Trachoma<sup>∇†</sup>

Matthew J. Burton,<sup>1,2\*</sup> Saul N. Rajak,<sup>1,3</sup> Julien Bauer,<sup>4</sup> Helen A. Weiss,<sup>1</sup> Sonda B. Tolbert,<sup>2</sup>  
Alice Shoo,<sup>2</sup> Esmail Habtamu,<sup>3</sup> Alphaxard Manjurano,<sup>1,2</sup> Paul M. Emerson,<sup>5</sup>  
David C. W. Mabey,<sup>1</sup> Martin J. Holland,<sup>1</sup> and Robin L. Bailey<sup>1</sup>

London School of Hygiene and Tropical Medicine, London, United Kingdom<sup>1</sup>; Kilimanjaro Christian Medical Centre, Moshi, Tanzania<sup>2</sup>; The Carter Center, Bahir Dar, Ethiopia<sup>3</sup>; Cambridge Genomic Services, Department of Pathology, Cambridge University, Cambridge, United Kingdom<sup>4</sup>; and The Carter Center, Atlanta, Georgia<sup>5</sup>

Received 16 August 2010/Returned for modification 15 September 2010/Accepted 29 September 2010

**Trachoma is a poorly understood immunofibrogenic disease process, initiated by *Chlamydia trachomatis*. Differences in conjunctival gene expression profiles between Ethiopians with trachomatous trichiasis (with [TTI] or without [TT] inflammation) and controls (C) were investigated to identify relevant host responses. Tarsal conjunctival swab samples were collected for RNA isolation and *C. trachomatis* PCR. Transcriptome-wide microarray experiments were conducted on 42 samples (TTI, *n* = 13; TT, *n* = 15; C, *n* = 14). Specific results were confirmed by using multiplex quantitative reverse transcription-PCR for 16 mRNA targets in an independent collection of case-control samples: 386 case-control pairs (TTI, *n* = 244; TT, *n* = 142; C, *n* = 386). The gene expression profiles of cases were consistent with squamous metaplasia (keratins, SPRR), proinflammatory cytokine production (*IL1β*, *CXCL5*, and *S100A7*), and tissue remodeling (*MMP7*, *MMP9*, *MMP12*, and *HAS3*). There was no difference in the level of *IFNγ* between cases and controls. However, cases had increased *INDO*, *NOS2A*, and *IL13RA2* and reduced *IL13*. *C. trachomatis* was detected in 1/772. Cases show evidence of ongoing inflammation and tissue remodeling, which were more marked where clinical inflammation was also present. Significantly, these processes appear to be active in the absence of current *C. trachomatis* infection. There was limited evidence of a T<sub>H</sub>1 response (*INDO* and *NOS2A*) and no association between a T<sub>H</sub>2 response and cases. The epithelium appears to be actively involved in late cicatricial stages of trachoma through the production of proinflammatory factors (*IL1β*, *CXCL5*, and *S100A7*). Longitudinal studies are needed to investigate which etiological factors and pathways are associated with progressive scarring and whether simply controlling chlamydial infection will halt progression in people with established cicatricial disease.**

Trachoma is the leading infectious cause of blindness worldwide (57). The disease process starts in early childhood with recurrent conjunctival infection by the bacterium *Chlamydia trachomatis*. This triggers a florid chronic inflammatory response characterized clinically by papillary hypertrophy and lymphoid follicles (active trachoma). In later life, after repeated episodes of infection and inflammation, scar tissue begins to accumulate within the conjunctiva, particularly that lining the upper eyelid. This causes eyelid distortion leading to the rubbing of lashes on the cornea (trichiasis). Ultimately, blinding corneal opacification develops.

The tissue damage in trachoma is primarily due to the human immune response rather than direct damage by the pathogen. Chlamydial infection is limited to the superficial conjunctival epithelium, while the inflammatory response extends into the deeper subepithelial layers (23). Moreover, clinical inflammation is often found in the absence of detectable infection (11). Studies of *C. trachomatis* infection in a monkey model demonstrated that after a primary infection the inflammatory phenotype could be induced by inoculating the conjunctiva

with the *C. trachomatis* HSP60 antigen (66). There are some data on the immunological response in early active trachoma; however, there is limited information about the cicatricial stage (10, 28, 30, 44, 45). It is unknown which fibrogenic pathways are important to this disease process and what drives them. There are some data which show that individuals who have repeated severe inflammation in childhood are more likely to develop scarring complications in later life (16, 71). However, there are no longitudinal data that directly demonstrate that repeated *C. trachomatis* infection is needed for progressive scarring in later life, although scarring complications are generally more frequent and severe in regions where there is a high prevalence of active disease or *C. trachomatis* infection.

Previous work on trachoma and analogous disease processes has suggested a number of potential mechanisms for the development of scarring. It was suggested that a predominantly T<sub>H</sub>1 type response may be protective and that a predominantly T<sub>H</sub>2 response may be associated with the development of scarring (28). In addition, there is mounting evidence for the importance of T<sub>H</sub>2 responses in other infectious diseases that produce scarring such as schistosomiasis, which may be mediated by interleukin-13 (IL-13) and alternative macrophage activation (73). There are also some data indicating that factors such as the matrix metalloproteinases may be involved in the tissue remodeling process in trachoma (9, 10, 21, 30).

Azithromycin can be effective in controlling chlamydial infection in communities where coverage rates are high (61).

\* Corresponding author. Mailing address: Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. Phone: 44 (0) 7958 8359. Fax: 44 (0) 7958 8317. E-mail: matthew.burton@lshtm.ac.uk.

† Supplemental material for this article may be found at <http://iai.asm.org/>.

∇ Published ahead of print on 11 October 2010.

However, there are significant obstacles to its effective regular long-term delivery. Similarly, improved control of genital chlamydial infection can be achieved through screening programs; however, these are expensive, and uptake is low. Therefore, an antichlamydial vaccine would be useful (64). Trachoma vaccine trials in the 1960s induced short-lived, serovar-specific protection with whole-organism vaccines (25, 69). Furthermore, in some trials vaccination was thought to be associated with more severe disease, suggesting immunopathological tissue damage (63). Therefore, a critical issue is whether an antichlamydial response can be induced without provoking fibrosis. A better understanding of how chlamydial infections damage tissue and cause fibrosis is necessary for the development of a safe vaccine that will prime the immune system to produce nonfibrogenic responses.

To further our understanding of scarring trachom, we investigated the conjunctival gene expression profile in a group of Ethiopian individuals with established trachomatous scarring and trichiasis (with or without inflammation). These cases were compared to control subjects from the same communities. We initially performed microarray analysis on a limited set of samples. Subsequently, quantitative reverse transcription-PCR (RT-PCR) was used to validate microarray findings and explore specific hypotheses in a large case-control series.

#### MATERIALS AND METHODS

**Ethical permission.** This study was approved by the National Health Research Ethics Review Committee, Ministry of Science and Technology of Ethiopia; the London School of Hygiene and Tropical Medicine Ethics Committee; and the Emory University Institutional Review Board. Informed consent was obtained prior to enrolment of each subject. This study adhered to the tenets of the Declaration of Helsinki.

**Study participants.** Individuals with trachomatous trichiasis were recruited during a surgical campaign in Amhara Region, Ethiopia. Control subjects, who did not have either trichiasis or significant conjunctival scarring, were recruited from the same communities as the cases. We recruited three groups of subjects (i) patients with trichiasis and inflammation (TTI), (ii) patients with trichiasis but no conjunctival inflammation (TT), and (iii) controls without trichiasis or significant conjunctival scarring (C). A much larger number of trichiasis cases (both TTI and TT) and matched controls were recruited for real-time PCR assessment of gene expression. Where possible, controls were of the same sex, similar age ( $\pm 10$  years) and came from the same community as their matched case.

**Clinical assessment and sample collection.** All participants were examined for clinical signs of trachoma, graded using 2.5 $\times$  binocular loupes according to the detailed World Health Organization (WHO) trachoma grading system (15). Trichiasis was defined as lashes touching the eye or clear evidence of epilation of trichiatric lashes. Conjunctival inflammation was considered significant if there were prominent papillae and/or haziness of the upper tarsal blood vessels (P<sub>2</sub>/P<sub>3</sub>) (15). Conjunctival scarring was considered significant if there were easily visible moderate or severe scars (C<sub>2</sub>/C<sub>3</sub>) on the upper tarsal conjunctiva (15). The conjunctiva was anesthetized with preservative-free proxymetacaine 0.5% eye drops (Minims; Chauvin Pharmaceuticals). Two conjunctival swab samples were collected from the upper tarsal conjunctival surface (Dacron polyester-tipped swab; Hardwood Products Company). The first was collected for RNA isolation and placed directly into a tube containing 0.3 ml of RNAlater (Ambion). The second swab was collected for *C. trachomatis* PCR and placed in a dry tube. Samples were kept on ice packs until frozen later the same day at  $-20^{\circ}\text{C}$ .

**Microarray experiments.** RNA was extracted from swab samples by using an RNeasy Micro kit (Qiagen, Crawley, United Kingdom) according to the manufacturer's instructions. Total RNA was assessed for concentration and quality on a NanoDrop ND-1000 (Thermo Fisher Scientific, Loughborough, United Kingdom) and a Bioanalyser (Agilent Technologies, Queensferry, United Kingdom). Microarray experiments were performed at Cambridge Genomic Services, University of Cambridge, using the HumanWG-6 v3.0 Expression BeadChip (Illumina, San Diego, CA) according to the manufacturer's instructions. Briefly, RNA underwent linear amplification using the Illumina TotalPrep RNA amplification kit (Ambion, Warrington, United Kingdom) according to the manufac-

turer's instructions. The cRNA was checked on a NanoDrop and Bioanalyser for concentration and to verify the success of amplification. If the concentration was below 150 ng/ $\mu\text{l}$ , this was increased by using a SpeedVac (Thermo Fisher Scientific). cRNA was hybridized to the HumanWG-6 BeadChip overnight. The next day the BeadChips were washed and stained. Finally, the chips were scanned by using a bead array reader (Illumina).

**Quantitative RT-PCR.** The abundance of 16 selected transcripts was estimated by quantitative RT-PCR. Gene targets (see Table 6) were chosen to address the hypothesized roles of T<sub>H</sub>1/T<sub>H</sub>2 balance (*IFNG*, *IL13*, and *IL13RA2*), classical and alternative macrophage activation (*NOS2A* and *ARG1*), and matrix metalloproteinases (*MMP7*, *MMP9*, *MMP12*, and *HAS3*) in the fibrotic process. In addition, four targets (*S100A7* [psoriasin], *CXCL5*, *HAS3*, and *IL19*) identified in the microarray experiment as having marked increase in expression in cases, and the potential to be important in this disease process, were also selected for quantitative RT-PCR estimation.

Total RNA was extracted from the swab samples using the RNeasy Micro kit (Qiagen). Reverse transcription was performed by using a QuantiTect reverse transcription kit (Qiagen) according to the manufacturer's instructions. This contains a mix of oligo(dT) and random primers. Multiplex real-time quantitative PCR was performed on a Rotor-Gene 6000 (Corbett Research, Cambridge, United Kingdom) using the QuantiTect Multiplex NoROX kit (Qiagen), according to the manufacturer's instructions. Multiplex assays of up to four separate targets (including *HPRT-1* as the reference gene) were designed by Sigma Life Science (Sigma Primer and Probe Design Service) using Beacon Designer 7.60 (Premier Biosoft International, Palo Alto, CA). The thermal cycle protocol used the following conditions: 95 $^{\circ}\text{C}$  for 15 min, followed by 45 cycles of first denaturation at 94 $^{\circ}\text{C}$  for 30 s and then annealing and extension at 60 $^{\circ}\text{C}$  for 30 s. Fluorescence data was acquired at the end of each cycle. The relative efficiency of the component reactions was assessed using standards containing all targets in a sequence of 10-fold serial dilutions. Reactions were performed in duplicate, in a total volume of 25  $\mu\text{l}$ , which contained 2  $\mu\text{l}$  of sample or standard. Probe and primer sequences are available on request.

**C. trachomatis detection.** Conjunctival swab samples collected from the subjects in the RT-PCR case-control study were tested for *C. trachomatis* DNA by using a PCR-based assay (Amplicor CT/NG Test; Roche) with previously described modifications (11). We did not collect DNA swabs from individuals in the microarray component of the study.

**Microarray analysis.** Quality control checks on the microarray data were made using GenomeStudio (Illumina). Sample independent controls were used to assess the success of the microarray process (hybridization, stringency, biotin control, and negative controls). Sample dependent controls examined the intensities of reference genes and the average intensity of all probes on each strip of the array. The data were transferred to Lumi ([www.bioconductor.org](http://www.bioconductor.org)), an open-source software package written in R ([www.r-project.org](http://www.r-project.org)), for the analysis of Illumina microarray data (19). Additional checks on the correlation between replicates and the intensity distribution were made. Nonsupervised clustering was performed to identify potential outliers. Transcripts were selected for analysis if they were expressed in at least one sample and they were significantly different from the negative controls at the 1% significance level. The data were transformed using the variance stabilization transformation and then normalized using quantile normalization in Lumi (40). Normalized data were examined by using the open-source R-based package LIMMA ([www.bioconductor.org](http://www.bioconductor.org)) in three pairwise comparisons: TTI versus C, TT versus C, and TTI versus TT (60). We corrected for multiple testing by using the Benjamini-Hochberg method for adjusting the *P* value and thereby controlling the false discovery rate (3). Gene enrichment analysis of gene ontology terms and pathways were performed for the three pairwise comparisons using DAVID (v6.7; <http://david.abcc.ncifcrf.gov>) and GeneGO (GeneGO, St. Joseph, MI) (18, 32). Enriched gene ontology terms were identified by assessing the proportion of genes in a particular grouping that were either upregulated (fold change,  $>1.5$ ) or downregulated (fold change,  $<0.66$ ) with an adjusted *P* value of  $<0.05$ .

The microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE23705 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23705>).

**Quantitative RT-PCR analysis.** The transcript abundances for genes of interest were standardized relative to that of *HPRT1* in the same reaction using the  $\Delta\Delta C_T$  method and were successfully normalized by  $\log_{10}$  transformation (41). An overall comparison of the mean values across the three different clinical categories was made using one-way analysis of variance. Paired comparisons between clinical categories were made using either paired or unpaired Student *t* tests as appropriate. Bonferroni correction for 48 multiple comparisons gave a critical significance threshold value of  $P = 0.001$ .

TABLE 1. Demographic characteristics of subjects in microarray study grouped by clinical phenotype<sup>a</sup>

Parameter	C (n = 14)	TTI (n = 13)	TT (n = 15)
No. of male subjects (%)	7 (50)	2 (15)	6 (40)
No. of female subjects (%)	7 (50)	11 (85)	9 (60)
Mean age in yr (95% CI)	43.5 (36.3–52.2)	40.8 (32.2–51.6)	56.1 (50.0–93.0)

<sup>a</sup> Subject group: TTI, trichiasis with inflammation; TT, trichiasis without inflammation; C, control; n, number of subjects.

RESULTS

**Study participants.** All participants were of Amharan Ethiopian ethnicity. We recruited and collected samples from 45 individuals for the microarray study. The mean RNA concentration in the extract was 76 ng/μl (standard deviation [SD] = 23; range, 26 to 125 ng/μl). Three samples were not included in the microarray experiment because their RNA concentration was insufficient (2 TTI and 1 C). The numbers, age, and gender profiles of the three clinical groups (TTI, TT, and C) are shown in Table 1. None of the control subjects in the microarray experiment had any visible conjunctival scarring.

For the quantitative RT-PCR component of the present study we recruited 772 individuals: 386 trichiasis cases (TT, n = 142; TTI, n = 244) and 386 controls, whose demographic and clinical characteristics are shown in Table 2. The severity of endemic trachoma in this Ethiopian population is such that there are relatively few adults who are totally free of any tarsal conjunctival scarring. Therefore, to meet other matching criteria for controls (location, age, and sex), we accepted controls with minor degrees of conjunctival scarring (WHO C<sub>1</sub> or mild C<sub>2</sub>). (15). The vast majority of individuals (762 of 772) in the present study lived in districts that have been mass treated with azithromycin for trachoma control during the year prior to surgery with an average population coverage of 77% (The Carter Center, Ethiopia). There had been no treatments during the 3 months prior to when sampling started.

**Microarray quality control and data selection.** The microarray internal sample-independent quality control tests all yielded “good” results. Reference genes performed well, indicating that there was no template degradation. Of the 44,803 probe sets that can be detected by the Human WG-6 microarray, 17,214 were selected for normalization and analysis.

**Global gene expression and clinical state.** To assess the extent to which global gene expression profiles could distinguish the clinical groups, a 42×42 matrix of the Pearson correlation coefficients of global gene expression for each pair of subjects was constructed (Fig. 1). Each row and column corresponds to an individual subject and the entry in the *i*th row and *j*th column being the Pearson correlation  $r_{ij}$  between the global expression profiles of individuals *i* and *j*. The matrix was reordered so that subjects whose profiles were most similar were placed in adjacent rows and columns and a hierarchical tree of similarity constructed (Fig. 1). This hierarchical tree had two main branches. All individuals with TTI were found in branch 1, and all normal controls were in branch 2. The cases with TT (without inflammation) were found in about equal proportion in both branches. Within branch 1 the TTI and the

TABLE 2. Demographic and clinical characteristics of cases and controls in the quantitative RT-PCR study<sup>a</sup>

Parameter	Cases (n = 386)		Controls (n = 386)	
	No.	%	No.	%
No. of female subjects	290	75.1	269	69.7
No. of subjects at age:				
<40 yr	90	23.3	107	27.7
40–49 yr	102	26.4	99	25.6
50–59 yr	94	24.4	84	21.8
≥60 yr	100	25.9	96	24.9
Mean (95% CI) <sup>b</sup>	49.6	48.2–51.0	48.0	46.6–49.4
Mean BMI <sup>c</sup> (95% CI)	19.7	19.4–19.9	20.5	20.1–20.7
Trichiasis (no. of lashes)				
None			386	100
None (epilating)	60	15.5		
1–4	128	33.2		
5–9	115	29.8		
10–19	44	11.4		
≥20	39	10.1		
Mean (95% CI)	8.8	7.3–10.2		
No. of subjects with conjunctival inflammation				
P0	29	7.5	242	62.7
P1	113	29.3	136	35.2
P2	187	48.4	8	2.1
P3	57	14.8	0	0.0
No. of subjects with conjunctival scarring				
C0			105	27.2
C1	4	1.0	235	60.9
C2	239	61.9	46	11.9
C3	143	37.1		

<sup>a</sup> The percent values represent the percent total number. Range values indicate 95% CI values.

<sup>b</sup> Student *t* test, *P* = 0.10.

<sup>c</sup> Body mass index (BMI) data were available on 384 cases and 240 controls (Student *t* test, *P* = 0.0001).

TT cases mostly segregated into separate clusters. Similarly, in branch 2 the controls and the TT cases generally segregated.

**Differentially regulated genes in different clinical states.** For all 17,214 probe sets detected by microarray and selected for analysis expression levels were compared between the clinical groups: TTI versus C, TT versus C, and TTI versus TT. Transcripts found to be at an increased or a decreased abundance relative to the C group, or to the TT group in the case of TTI versus TT, were filtered with different adjusted *P* value thresholds (Table 3). The numbers of transcripts unique to each comparison with a >2-fold increase or decrease in abundance are shown in Fig. 2. In this Venn diagram, the origins of a selection of potentially interesting transcripts are indicated. The most numerous differences were between TTI and C, with less differential regulation occurring between TT and C and between TTI and TT cases. Selected transcripts of interest identified by microarray analysis are shown in Table 4 for each of the comparisons, along with their fold changes and adjusted *P* values. Various categories of genes showed differential expression: cell surface markers (HLA-DRB1, CD19, and CD24), cytokines/chemokines (IL-1B, IL-19, CXCL5, CCL5,




FIG. 1. Global gene expression. A correlation matrix for the global gene expression profile (all genes) between all pairs of samples. Samples are ordered into a hierarchical tree for similarity. Sample type: TTI, trichiasis with inflammation (red); TT, trichiasis without inflammation (orange); C, control (green).

and CCL20), immune response effector molecules (S100A7, DEFB4, PLUNC, NOS2A, DUOX2, and INDO), extracellular matrix regulators (MMP7, MMP9, MMP12, SPARCL, and CEACAM5), and keratinization components (SPRR2A, SPRR2D, KRT6A, and KRT6B). Factors involved in the in-

nate immune response were particularly prominent (S100A7, CXCL5, DEFB4, PLUNC, NOS2A, and SAA1). There was some evidence of activated T<sub>H</sub>1 responses in cases (INDO, DUOX2, and NOS2A). There was no evidence of increased abundance of transcripts associated with a T<sub>H</sub>2 type response


TABLE 3. Number of regulated genes in each of three comparisons, filtered by different adjusted *P* value thresholds<sup>a</sup>

<i>P</i> value threshold	TTI vs C		TT vs C		TTI vs TT	
	No. of genes	%	No. of genes	%	No. of genes	%
Adjusted						
<0.05	9,003	52	4,141	24	4,677	27
<0.01	6,766	38	2,041	12	1,644	9
<0.001	4,423	25	841	5	189	1
Filtered <sup>b</sup>						
Upregulated genes	2,022		410		128	
Downregulated genes	2,401		431		61	

<sup>a</sup> The comparisons included groups TTI versus C, TT versus C, and TTI versus TT. The percent values are of the total number of genes selected for normalization and analysis (*n* = 17,214).

<sup>b</sup> That is, filtered at the adjusted *P* value of <0.001.

**(a) Up-regulated genes**



**(b) Down-regulated genes**




FIG. 2. Differentially expressed genes with a >2-fold change for the three comparison pairs (TTI versus C, TT versus C, and TTI versus TT). (a) Upregulated genes; (b) downregulated genes. Selected genes of interest are shown.

in cases. Table S1 in the supplemental material presents the fold changes and adjusted *P* values for all targets where there was a >2-fold increase or decrease.

**Gene enrichment analysis.** The results of gene enrichment analysis performed using DAVID and GeneGO are shown in Table 5. In comparing samples from trichiasis cases (with or without inflammation), we found that DAVID identified significant enrichment of gene ontology (GO) terms involved in the development of a keratinized/cornified squamous epithelial surface in individuals with trichiasis (irrespective of the presence of inflammation). The top five GO terms for the comparisons of the TT or TTI groups with the C group reflect these processes, although there is considerable overlap in the specific genes included in these terms. Where clinical inflam-

mation was also present, additional GO terms related to immune responses were also enriched. Pathway analysis using GeneGO identified a similar pattern of changes with trichiasis associated with cytoskeleton remodeling (keratin, WNT pathway) and regulation of cell cycle components and inflamed conjunctiva associated with an immunological response.

**Quantitative RT-PCR analysis of gene expression.** Quantitative real-time RT-PCR was performed for the 16 gene expression targets (Table 6) on all 772 cases and controls. The geometric means, the 95% confidence interval (95% CI) values, and statistical comparisons of the three clinical categories are shown in Table 6. The fold changes measured by the microarray experiment were highly correlated with those measured by quantitative RT-PCR: correlation coefficient 0.88, *P* < 0.0001. A high proportion (42%) of samples did not have detectable expression of *IL19*. However, there was a significant difference (odds ratio, 9.4; 95% CI, 6.7 to 13.1; *P* < 0.001) in the proportion expressing *IL19* between the TT/TTI cases (319/386 [83%]) and controls (130/386 [34%]).

There was no evidence that *IFN*γ was differentially regulated between cases and controls; however, there was significantly increased expression of both *INDO* and *NOS2A*. The expression of *IL13* was lower in cases compared to controls, particularly where inflammation was also present. Conversely, the expression of the decoy receptor *IL13RA2* was increased in the cases compared to the controls. The ratio of *IL13/IL13RA2* expression was markedly reduced in cases relative to controls. We found the expression of *ARG1* to also be reduced in cases relative to controls.

*IL1B*, *CXCL5*, and *S100A7* were expressed at significantly increased levels in cases compared to controls. Cases with inflammation (TTI) were found to have increased expression of these three factors relative to cases without inflammation; however, the critical significance level of *P* < 0.001 was not reached. We did not find a variation in the expression of *IL10* between cases and controls. The extracellular matrix regulators *MMP7*, *MMP9*, *MMP12*, and *HAS3* were increased in cases relative to controls.

We examined whether there was any evidence of differential gene expression between controls with mild conjunctival scarring and controls without any sign of scarring. The only difference was for *NOS2A*, which was slightly increased in the controls with mild scarring (fold change, 1.54; *P* < 0.0001).

**C. trachomatis PCR.** All 772 dry samples collected from individuals in the case-control study were tested for *C. trachomatis* by PCR. Of these, only one sample was positive, five were consistently inhibited on retesting, and the remaining 766 tested negative. All positive and negative controls performed normally. With the exception of the five inhibited samples, all specimen internal control tests were positive.

**DISCUSSION**

The pathophysiology of scarring trachoma is poorly characterized in terms of the immunological factors and fibrogenic pathways involved. In the present study, using transcriptome-wide gene expression analysis, we found marked differential gene expression in the conjunctiva of individuals with significant trachomatous scarring and trichiasis compared to controls with minimal or no conjunctival scarring. Gene enrichment

TABLE 4. Genes of interest with the largest fold changes, as determined by three pairwise comparisons<sup>a</sup>

Gene	Description	Function	TTI vs C		TT vs C		TTI vs TT	
			FC	P	FC	P	FC	P
Cell surface markers/receptor <i>HLA-DRB1</i> <i>HLA-DQB2</i> <i>CD19</i> <i>CD24</i>	Major histocompatibility complex DRB1 Major histocompatibility complex DOB2	MHC class II molecule MHC class II molecule B-cell surface B-cell and granulocyte surface marker/cell adhesion	4.0 0.29 2.2 3.5	0.008 $2 \times 10^{-5}$ $4 \times 10^{-4}$ $4 \times 10^{-7}$	0.43 0.50 1.2 1.6	0.809 0.021 0.535 $7 \times 10^{-4}$	4.7 0.57 1.9 1.2	0.009 0.056 0.011 0.540
Cytokines/chemokines <i>IL1B</i>	IL-1 $\beta$	Proinflammatory cytokine; released by epithelium and other cells	1.9	0.076	0.59	0.189	3.2	0.005
<i>IL10</i> <i>IL19</i> <i>IL23A</i>	IL-10 IL-19 IL-23	Anti-inflammatory cytokine Uncertain, possibly proinflammatory Proinflammatory cytokine; promotes IL-17 response	1.6 13.4 1.6	$3 \times 10^{-4}$ $3 \times 10^{-7}$ $4 \times 10^{-4}$	1.2 4.2 1.2	0.288 0.003 0.098	1.4 1.8 1.2	0.027 0.016 0.103
<i>CXCL5</i> <i>CCL5</i>	Chemokine (CXC) ligand 5 Chemokine (CC) ligand 5/RANTES	Chemotactic neutrophil Chemotactic for lymphocytes, eosinophils, basophils	5.3 0.22	$1 \times 10^{-6}$ $5 \times 10^{-6}$	1.1 0.29	0.790 $8 \times 10^{-4}$	4.8 1.1	$1 \times 10^{-4}$ 0.334
<i>CCL20</i>	Chemokine ligand 20	Macrophage inflammatory protein 3, lymphocyte chemotaxis	2.4	0.003	1.3	0.437	1.8	0.060
Immune response effector molecules <i>S100A7</i>	Psoriasis 1	Antimicrobial, chemokine, cornified envelope precursor	37.1	$7 \times 10^{-9}$	9.6	$6 \times 10^{-5}$	3.8	0.014
<i>S100A12</i>	EN-RAGE	Proinflammatory protein, secreted by neutrophils	3.3	$6 \times 10^{-5}$	1.5	0.191	2.2	0.013
<i>DEFB4</i>	Defensin $\beta$ 4	Mucosal innate immunity, antibacterial, chemotactic	11.3	$2 \times 10^{-6}$	3.8	0.008	2.9	0.029
<i>DEFB103A</i>	Defensin $\beta$ 103A/defensin $\beta$ 3	Mucosal innate immunity, antibacterial, chemotactic	3.1	0.001	2.0	0.076	1.6	0.225
<i>PLUNC</i>	Palate, lung, nasal epithelium associated	Mucosal defense, antibacterial, antiviral, from epithelium	7.4	$2 \times 10^{-8}$	2.7	0.007	2.8	0.006
<i>NO32A</i> <i>DUOX2</i>	Nitric oxide synthase 2A Dual oxidase 2	Generates nitric oxide, antichlamydial Produce ROS in response to T <sub>H</sub> 1 stimulation	3.5 3.4	$3 \times 10^{-6}$ $5 \times 10^{-8}$	1.8 2.3	0.005 $9 \times 10^{-5}$	1.3 1.5	0.336 0.0515
<i>GPX2</i> <i>INDO</i>	Glutathione peroxidase 2 Indoleamine-pyrrole 2,3-dioxygenase	H <sub>2</sub> O <sub>2</sub> reducing activity in epithelium Catalyzes tryptophan (antichlamydial), immunoregulatory	5.0 4.1	$5 \times 10^{-10}$ $3 \times 10^{-6}$	3.1 3.0	$2 \times 10^{-6}$ $4 \times 10^{-4}$	1.6 1.4	0.021 0.322
<i>SAA1</i>	Serum amyloid A1	Promotes inflammation, promotes collagenase activity	3.9	$1 \times 10^{-4}$	1.5	0.071	1.7	0.066
<i>SERPINA3</i>	$\alpha$ 1-Antitrypsin	Acute-phase protein, inhibits proteases (MMP9)	9.7	$4 \times 10^{-10}$	2.4	0.003	4.0	$1 \times 10^{-4}$
<i>CFH</i>	Complement factor H	Regulates the alternative complement pathway	0.30	$2 \times 10^{-7}$	0.36	$3 \times 10^{-6}$	0.71	0.119
Extracellular matrix regulators, components, and adhesion <i>MMP1</i> <i>MMP7</i>	Matrix metalloproteinase 1 Matrix metalloproteinase 7	MMP with multiple substrates Degrades collagen I/IV, laminin, and fibronectin; activates defensins	1.5 3.5	0.025 $1 \times 10^6$	1.8 3.6	0.004 $6 \times 10^{-6}$	1.2 1.0	0.379 0.925
<i>MMP9</i>	Matrix metalloproteinase 9	MMP with multiple substrates; ECM components and cytokines	2.4	$3 \times 10^{-4}$	1.3	0.403	1.9	0.013
<i>MMP10</i> <i>MMP12</i> <i>SE-ARCL1</i> <i>COL7A1</i> <i>HAS3</i>	Matrix metalloproteinase 10 Matrix metalloproteinase 12 Hevin Collagen 7 $\alpha$ 1 Hyaluronan synthase 3	MMP involved in wound healing MMP with multiple substrates Extracellular matrix regulator Epithelial basement zone Synthesizes hyaluronic acid, an extracellular matrix component	1.6 3.1 0.14 2.5 3.6	0.045 $2 \times 10^{-5}$ $6 \times 10^{-7}$ $6 \times 10^{-6}$ $3 \times 10^{-9}$	2.9 1.0 0.24 2.0 2.0	$1 \times 10^{-4}$ 0.833 $2 \times 10^{-4}$ $8 \times 10^{-4}$ $2 \times 10^{-4}$	1.8 1.4 0.66 1.2 1.8	0.031 0.003 0.170 0.276 0.002
<i>ARG1</i>	Arginase	Converts L-arginine to L-ornithine	1.1	0.288	1.2	0.205	1.0	0.766

<i>ANKRD36B</i>	Ankyrin repeat domain 36B	5.6	$4 \times 10^{-10}$	1.9	0.004	3.0	$6 \times 10^{-5}$
<i>CEACAM1</i>	Carcinoembryonic antigen-1	2.2	$1 \times 10^{-5}$	2.2	$5 \times 10^{-5}$	1.1	0.247
<i>CEACAM5</i>	Carcinoembryonic antigen-5	8.6	$2 \times 10^{-10}$	5.4	$1 \times 10^{-7}$	1.6	0.074
<i>CEACAM7</i>	Carcinoembryonic antigen-7	4.8	$7 \times 10^{-7}$	3.4	$7 \times 10^{-5}$	1.3	0.343
<i>NDS174</i>	N-Deacetylase/N-sulfotransferase 4	0.1	$1 \times 10^{-9}$	0.14	$1 \times 10^{-7}$	0.71	0.251
<b>Epithelial components</b>							
<i>SPRR1A</i>	Small proline-rich protein 1A	4.8	$4 \times 10^{-5}$	2.4	0.029	2.0	0.074
<i>SPRR2A</i>	Small proline-rich protein 2A	13.6	$3 \times 10^{-9}$	4.8	$6 \times 10^{-5}$	2.8	0.008
<i>SPRR2D</i>	Small proline-rich protein 2D	10.5	$7 \times 10^{-8}$	3.7	0.002	3.0	0.009
<i>SPRR2F</i>	Small proline-rich protein 2F	11.8	$8 \times 10^{-9}$	4.4	$1 \times 10^{-4}$	2.7	0.009
<i>KRT6A</i>	Keratin 6A	10.3	$1 \times 10^{-8}$	5.5	$1 \times 10^{-5}$	1.9	0.068
<i>KRT6B</i>	Keratin 6B	5.0	$5 \times 10^{-8}$	2.7	$4 \times 10^{-4}$	1.9	0.019
<i>KRT6E</i>	Keratin 6E	2.8	0.020	3.4	0.014	0.43	0.733
<i>KRT17</i>	Keratin 17	3.6	$3 \times 10^{-5}$	1.6	0.168	2.3	0.009
<i>KRT24</i>	Keratin 24	3.9	$2 \times 10^{-6}$	1.6	0.099	2.5	0.002
<i>MUC1</i>	Mucin 1	2.2	$2 \times 10^{-8}$	1.7	$6 \times 10^{-5}$	1.3	0.037
<i>MUC4</i>	Mucin 4	3.2	$2 \times 10^{-7}$	1.8	0.005	1.8	0.008
<i>MUC5A</i>	Mucin 5A	1.5	0.050	1.8	0.017	0.86	0.531
<i>MUC7</i>	Mucin 7	0.19	$3 \times 10^{-4}$	0.48	0.141	0.40	0.053

<sup>a</sup> FC, fold change. *P* values represent the adjusted *P* value for the specific pairwise comparison, as determined by the Benjamini-Hochberg method (3). A positive fold change indicates increased expression in the first phenotype group in each comparison.

analysis indicates that the most prominent changes were in the nature of the epithelium, suggestive of squamous metaplasia. Second, trichomatous scarring and trichiasis, particularly in the presence of clinically visible conjunctival inflammation, was associated with various proinflammatory factors, characteristic of an activated innate immune response. Third, there was very limited evidence of an ongoing  $T_H1$  but not  $T_H2$  response in scarred conjunctiva. Finally, there was evidence of cytoskeletal remodeling, including enrichment of the profibrotic WNT pathway and increased expression of various regulators of the extracellular matrix. We found that the results for various targets measured by quantitative PCR in a large case-control series were consistent with the microarray data.

**Squamous metaplasia of the conjunctival epithelium.** An important clinical feature of cicatricial trachoma is the transformation of the conjunctival epithelium from healthy mucosa into a pathologically dry, keratinized surface. Normally, the tarsal conjunctival surface is formed of a nonkeratinized stratified epithelium. The superficial cells tend to be cylindrical in shape, and there are scattered goblet cells. In advanced trichomatous scarring, the epithelium is thinned and transformed into a keratinized, stratified, squamous epithelium with loss of goblet cells (1, 4). Squamous metaplasia requires the synthesis of specific proteins, including small proline-rich proteins (SPRR) and keratins that are key components of the cornified envelope. We found significantly increased expression in cases of several SPRRs (SPRR1A, SPRR2A, SPRR2D, and SPRR2F) and keratins (KRT6A, KRT6B, KRT6E, KRT17, and KRT24). This was more marked in clinically inflamed conjunctiva. Extensive squamous metaplasia is detrimental to the health of the ocular surface and may contribute to the development of blinding corneal opacification in trachoma.

Ocular surface squamous metaplasia develops in other conjunctival disease processes, often in association with chronic inflammation and dryness, as in, for example, ocular cicatricial pemphigoid, Stevens-Johnson syndrome, systemic sclerosis, and alkali burns. It is likely that squamous metaplasia is a nonspecific response to injury or inflammation. In experimental models of dry eye disease there is an influx of inflammatory cells, particularly  $CD4^+$  lymphocytes, and upregulation of SPRRs (SPRR-1, SPRR-2) under the influence of proinflammatory cytokines, particularly IL-1 $\beta$  and gamma interferon (IFN- $\gamma$ ) (17, 39).

Mucins are important components of the ocular surface. Their hydrophilic properties allow surface wetting, and they provide a physical barrier to bacterial invasion (42). We found some changes in the expression of several mucins in TT cases. There was increased expression of *MUC1* and *MUC4*, which are produced by epithelial cells and attach to the surface membrane. In addition, there was a nonsignificant increase in the expression of *MUC5A*, which is a large soluble protein released from goblet cells. *MUC7* expression was reduced, although the significance of this is unclear since this is primarily derived from the lacrimal gland. Increased expression of these mucins may be to compensate for a dry ocular surface.

**Proinflammatory response.** Chronic conjunctival inflammation is considered to be a key event in the pathophysiology of trichomatous scarring. Children with active trachoma, particularly severe inflammatory trachoma (TI), are at increased risk of developing the scarring complications of this disease in later

TABLE 5. Results of gene set enrichment analysis<sup>a</sup>

Comparison	Gene Ontology terms (DAVID)				Gene-GO	
	<i>N</i>	Name	FC	<i>P</i>	Pathway	<i>P</i>
TTI vs C	104	GO:0007398~ectoderm development	4.04	$1.28 \times 10^{-09}$	Cytoskeleton remodeling~keratin filaments	$9.60 \times 10^{-12}$
		GO:0008544~epidermis development	4.06	$5.14 \times 10^{-09}$	DNA damage~ATM/ATR regulation of G <sub>1</sub> /S checkpoint	$1.41 \times 10^{-10}$
		GO:0031424~keratinization	8.03	$1.67 \times 10^{-07}$	Cell cycle~the metaphase checkpoint	$8.65 \times 10^{-10}$
		GO:0030216~keratinocyte differentiation	6.09	$3.46 \times 10^{-07}$	Cytoskeleton remodeling~cytoskeleton remodeling	$2.04 \times 10^{-9}$
		GO:0009913~epidermal cell differentiation	5.58	$9.93 \times 10^{-07}$	Apoptosis and survival~TNFR1 signaling pathway	$5.47 \times 10^{-9}$
		GO:0006955~immune response	2.08	$1.45 \times 10^{-06}$	DNA damage~NHEJ mechanisms of DSB repair	$9.72 \times 10^{-9}$
		GO:0030855~epithelial cell differentiation	3.77	$5.29 \times 10^{-06}$	Cell cycle~cell cycle (generic schema)	$1.02 \times 10^{-8}$
		GO:0006952~defense response	2.01	$2.17 \times 10^{-05}$	Apoptosis and survival~FAS signaling cascades	$3.27 \times 10^{-8}$
		GO:0009611~response to wounding	2.01	$9.39 \times 10^{-05}$	Cell cycle~role of SCF complex in cell cycle regulation	$5.31 \times 10^{-8}$
		GO:0009617~response to bacterium	2.83	$1.37 \times 10^{-04}$	Cytoskeleton remodeling~TGF, WNT, and cytoskeletal remodeling	$6.41 \times 10^{-8}$
TT vs C	37	GO:0007398~ectoderm development	10.68	$1.89 \times 10^{-27}$	Signal transduction~AKT signaling	$7.97 \times 10^{-9}$
		GO:0008544~epidermis development	10.91	$2.65 \times 10^{-26}$	Development~PIP3 signaling in cardiac myocytes	$5.18 \times 10^{-8}$
		GO:0030216~keratinocyte differentiation	18.64	$2.87 \times 10^{-21}$	Cell cycle~role of Nek in cell cycle regulation	$5.37 \times 10^{-7}$
		GO:0009913~epidermal cell differentiation	17.04	$2.43 \times 10^{-20}$	Transport~RAN regulation pathway	$5.82 \times 10^{-7}$
		GO:0030855~epithelial cell differentiation	10.85	$1.40 \times 10^{-19}$	Cell cycle~regulation of G <sub>1</sub> /S transition (part 1)	$1.35 \times 10^{-6}$
		GO:0031424~keratinization	22.48	$6.79 \times 10^{-18}$	Cytoskeleton remodeling~keratin filaments	$3.40 \times 10^{-6}$
		GO:0060429~epithelium development	6.54	$5.43 \times 10^{-14}$	DNA damage~ATM/ATR regulation of G <sub>1</sub> /S checkpoint	$3.61 \times 10^{-6}$
		GO:0018149~peptide cross-linking	12.51	$9.62 \times 10^{-05}$	Cell cycle~nucleocytoplasmic transport of CDK/cyclins	$3.61 \times 10^{-6}$
		GO:0007586~digestion	5.36	$2.64 \times 10^{-04}$	Cell cycle~spindle assembly and chromosome separation	$5.61 \times 10^{-6}$
		GO:0009617~response to bacterium	3.56	$5.66 \times 10^{-04}$	Development~IGF-1 receptor signaling	$6.18 \times 10^{-6}$
TTI vs TT	105	GO:0006955~immune response	5.07	$1.69 \times 10^{-24}$	Cell adhesion~chemokines and adhesion	$1.80 \times 10^{-9}$
		GO:0006952~defense response	4.65	$2.36 \times 10^{-19}$	Immune response~CCR3 signaling in eosinophils	$4.79 \times 10^{-9}$
		GO:0042330~taxis	8.31	$4.23 \times 10^{-14}$	Immune response~immunological synapse formation	$6.28 \times 10^{-8}$
		GO:0006935~chemotaxis	8.31	$4.23 \times 10^{-14}$	Cytoskeleton remodeling~cytoskeleton remodeling	$1.67 \times 10^{-7}$
		GO:0009611~response to wounding	3.83	$2.74 \times 10^{-11}$	Apoptosis and survival~BAD phosphorylation	$2.01 \times 10^{-7}$
		GO:0007626~locomotory behavior	5.28	$5.57 \times 10^{-11}$	Development~IGF-1 receptor signaling	$3.29 \times 10^{-7}$
		GO:0006954~inflammatory response	4.64	$3.45 \times 10^{-10}$	Immune response~IL-10 signaling pathway	$5.74 \times 10^{-7}$
		GO:0007610~behavior	3.57	$9.79 \times 10^{-09}$	Development~thrombopoietin-regulated cell processes	$7.52 \times 10^{-7}$
		GO:0009617~response to bacterium	5.30	$1.28 \times 10^{-07}$	Immune response~IL-4~antiapoptotic action	$7.93 \times 10^{-7}$
		GO:0007398~ectoderm development	4.73	$1.44 \times 10^{-06}$	Chemotaxis~leukocyte chemotaxis	$1.02 \times 10^{-6}$

<sup>a</sup> The top-ten gene enrichment terms were identified by using (i) the Database for Annotation, Visualization, and Integrated Discovery (DAVID), v6.7, and (ii) Gene-GO. FC, fold change. *N*, number of gene ontology (GO) terms where *P* < 0.05 and fold enrichment was >1.5.



TABLE 6. Geometric means and 95% confidence intervals for the expression of each gene by clinical category<sup>a</sup>

Gene	C (n = 386)		TT (n = 142)		TTI (n = 244)		TTI vs C		TT vs C		TTI vs TT		P <sup>d</sup>
	Mean	95% CI	Mean	95% CI	Mean	95% CI	FC	P <sup>b</sup>	FC	P <sup>b</sup>	FC	P <sup>c</sup>	
<i>IFN<math>\gamma</math></i>	0.0212	0.0191–0.0235	0.0194	0.0167–0.0225	0.0178	0.0157–0.0203	0.78	0.0433	1.03	0.8282	0.92	0.4293	0.1105
<i>TNF<math>\alpha</math></i>	0.2064	0.1964–0.2169	0.2261	0.2013–0.2539	0.2370	0.2150–0.2613	1.11	0.0767	1.16	0.0403	1.05	0.5474	0.0236
<i>IL1B</i>	0.6248	0.5763–0.6775	1.1038	0.9131–1.3343	1.4000	1.2127–1.6164	2.18	<0.0001	1.86	<0.0001	1.27	0.0489	<0.0001
<i>IL10</i>	0.0361	0.0321–0.0407	0.0429	0.0346–0.0532	0.0418	0.0358–0.0487	1.08	0.4941	1.34	0.0660	0.97	0.8449	0.2055
<i>IL13</i>	0.0018	0.0016–0.0022	0.0012	0.0007–0.0015	0.0009	0.0007–0.0011	0.45	0.0002	0.72	0.0545	0.75	0.3895	<0.0001
<i>IL13RA2</i>	0.0083	0.0075–0.0093	0.0184	0.0153–0.0223	0.0178	0.0149–0.0214	2.17	<0.0001	2.12	<0.0001	0.97	0.7785	<0.0001
<i>IL19<sup>e</sup></i>	0.00003	0.00002–0.00004	0.0001	0.00007–0.00014	0.0001	0.00009–0.00016	2.98	0.0001	3.10	0.0227	1.29	0.2400	<0.0001
<i>ARG1</i>	0.0331	0.0310–0.0353	0.0408	0.0349–0.0476	0.0432	0.0383–0.0489	1.30	0.0007	1.24	0.0109	1.06	0.5599	0.0001
<i>NOS2A</i>	0.7908	0.7247–0.8629	2.0494	1.7665–2.3776	2.4573	2.1770–2.7737	3.28	<0.0001	2.36	<0.0001	1.20	0.0671	<0.0001
<i>INDO</i>	1.0955	0.9907–1.2113	3.4223	2.9046–4.0323	4.3953	3.8411–5.0295	4.10	<0.0001	3.02	<0.0001	1.28	0.0232	<0.0001
<i>CXCL5</i>	0.0070	0.0058–0.0084	0.0248	0.0178–0.0344	0.0419	0.0323–0.0543	6.39	<0.0001	3.15	<0.0001	1.69	0.0145	<0.0001
<i>S100A7</i>	0.3972	0.3568–0.4421	3.4075	2.4726–4.6959	5.8468	4.5231–7.5579	14.61	<0.0001	8.69	<0.0001	1.72	0.0109	<0.0001
<i>MMP7</i>	1.0005	0.9169–1.0917	2.7078	2.2781–3.2186	3.1925	2.8415–3.5868	3.14	<0.0001	2.79	<0.0001	1.18	0.1079	<0.0001
<i>MMP9</i>	0.0340	0.0305–0.0378	0.0570	0.0478–0.0679	0.0633	0.0554–0.0723	1.88	<0.0001	1.65	0.0001	1.11	0.3429	<0.0001
<i>MMP12</i>	0.4047	0.3662–0.4473	0.7397	0.6247–0.8759	0.8437	0.7329–0.9714	2.08	<0.0001	1.84	<0.0001	1.14	0.2501	<0.0001
<i>HAS3</i>	0.1456	0.1313–0.1613	0.2232	0.1904–0.2619	0.2441	0.2133–0.2793	1.68	<0.0001	1.53	0.0001	1.09	0.4136	<0.0001
<i>IL13/IL13RA2<sup>f</sup></i>	0.1911	0.1556–0.2348	0.0505	0.0340–0.0750	0.0425	0.0330–0.0547	0.20	<0.0001	0.28	0.0001	0.84	0.4435	<0.0001

<sup>a</sup> The expression levels are standardized relative to the expression of *HPRT1* in the same reaction. FC, fold change (a value of >1 indicates increased expression in the first clinical category of each comparison compared to the second).

<sup>b</sup> P values for paired *t* test. Using the Bonferroni correction, the critical significance threshold level is a P value of <0.001.

<sup>c</sup> P values for unpaired *t* test. Using the Bonferroni correction, the critical significance threshold level is a P value of <0.001.

<sup>d</sup> As determined by analysis of variance of the expression level of the gene across the three clinical categories.

<sup>e</sup> For *IL19*, only cases or controls where expression was detected are included.

<sup>f</sup> That is, the ratio of *IL13/IL13RA* expression.

life (16, 71). In adults with scarring the conjunctiva frequently appears clinically inflamed, although in many settings *C. trachomatis* infection is only infrequently detected, as was the case in our study (12, 62, 72). Individuals with TT or conjunctival scarring (TS) are at increased risk of nonchlamydial bacterial infection, which has been associated with clinically visible conjunctival inflammation.(8, 12).

In the present study we found increased expression of proinflammatory mediators in cases (*S100A7*, *S100A12*, *CXCL5*, *CCL20*, *IL1B*, and *SAAT1*). Interestingly, these factors were significantly raised in cases without clinical inflammation compared to controls, albeit to a lesser extent than in the inflamed cases. Several factors were characteristic of innate immune responses. *In vitro* studies of epithelial cells infected with *C. trachomatis* have measured the production of various chemokines and cytokines (52, 56). These experiments have consistently found that *C. trachomatis* infection triggers the prolonged production of a range of proinflammatory mediators, which are probably very important in the initial innate immune response to infection (IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, CXCL1, CXCL2, CXCL5, and CXCL6). It is likely that some of these mediators are produced by the conjunctival epithelium *in vivo*, suggesting that the epithelium is not just an injured bystander in *C. trachomatis* infection but is actively involved in the immunofibrogenic response (56). It is also likely that nonchlamydial bacterial infections stimulate the inflammatory response, especially where there is established tissue disruption caused by repeated *C. trachomatis* infection.(10) In addition to the epithelium, other cells, such as macrophages and neutrophils, probably contribute to the production of these proinflammatory mediators.

The innate immune response of epithelial cells is triggered through the stimulation of pattern recognition receptors (PRRs) by bacterial antigens. These receptors recognize conserved pathogen-associated molecular patterns (PAMPs).

PRRs, such as the Toll-like receptors (TLRs), detect PAMPs both on the epithelial cell surface and in the intracellular compartment. Relatively little is known about the role of PRRs in human *C. trachomatis* infection in general, and there are virtually no data for trachoma. *C. trachomatis* recognition by PRRs TLR2 and TLR4 is the most well-characterized pathway, with *in vitro* studies indicating that both can detect a range of *C. trachomatis* antigens (2, 35, 48). Their specificity appears to differ; TLR4 detects *C. trachomatis* lipopolysaccharide (LPS) and HSP60, while TLR2 appears to detect a ligand produced by viable *C. trachomatis* (6). In women, *C. trachomatis*-induced tubal scarring has recently been associated with genetic variation in TLR2 defined by SNP haplotypes (37). In a mouse model of *C. trachomatis* genital tract infection, recognition of *C. trachomatis* through TLR2 was associated with increased production of proinflammatory cytokines (IL-1, IL-6, MIP-2, and TNF- $\alpha$ ) and the development of scarring in the oviduct (14). TLR2-knockout mice developed much less scarring, although the duration of infection was not affected.

We found increased expression of *IL1B* in cases of trichiasis compared to controls, irrespective of clinical inflammation. The role of IL-1 $\beta$  has previously been investigated in trachoma. Immunohistochemistry of biopsy tissue from children with active trachoma localized the production of IL-1 $\alpha$  and IL-1 $\beta$  to the superficial layers of epithelial cells, with some additional production by stromal macrophages (22). We have previously reported increased *IL1B* expression in both active trachoma and conjunctival scarring (9, 10). In both of these clinical groups, increased *IL1B* expression occurred with or without *C. trachomatis* infection. In individuals with established conjunctival scarring, nonchlamydial bacterial infection was associated with increased expression of *IL1B*, suggesting that such infections can promote a proinflammatory response (10). Others have also found in a separate population that tear fluid from people with TTI has increased IL-1 $\beta$  compared to

controls (59). There is a growing body of evidence which indicates that *C. trachomatis* and other nonchlamydial bacterial infections stimulate the production of IL-1 $\beta$  through a combination of PRRs, leading to a cascade of proinflammatory products which both help to combat infection but at the same time can damage tissues (50, 65). In a number of different scarring disease processes, IL-1 $\beta$  has been identified as an important cytokine in fibrogenesis, possibly through the activation of fibroblasts either via platelet-derived growth factor or transforming growth factor  $\beta$  (TGF- $\beta$ ; activated via MMP9) (24, 58).

In the present study, CXCL5 was the chemokine with the greatest increase in expression. CXCL5 induces neutrophil chemotaxis and activation; it has also been found to induce fibroblast precursor chemotaxis and differentiation (46). Epithelial cells are probably the main source, although both macrophages and fibroblasts also produce it. A study of a *C. trachomatis*-infected epithelial cell line found CXCL5 was produced in abundance and led to neutrophil chemotaxis (74). Interestingly, there is some evidence that *C. trachomatis* antigens alone (such as MOMP or LPS) might be sufficient to stimulate CXCL5 production (74). In our study, CXCL5 expression was increased in the absence of detectable *C. trachomatis*, raising the question of what might be stimulating its production. Models of *Escherichia coli* LPS-induced pulmonary inflammation indicate that CXCL5 is produced by the epithelium through TLR4-dependent signaling (34). It is therefore possible that in the context of cicatricial trachoma other bacterial pathogens could stimulate CXCL5 production directly or indirectly through other cytokines (IL-1 $\beta$  and TNF- $\alpha$ ) or products of extracellular matrix (ECM) breakdown (actin) (67).

S100A7 (Psoriasin 1) was the most strongly upregulated gene in the present study. Initially identified in psoriatic skin lesions, it is a member of the S100 family, a diverse group of calcium-binding proteins involved in various processes, including cell proliferation and differentiation. It is produced by keratinocytes and has a proinflammatory, microbicidal action, promoting production of IL-8, TNF- $\alpha$ , CCL3, and CCL20 (75). S100A7 has been implicated in several disease processes. It is highly expressed in ductal carcinoma *in situ*, where it is increased by proinflammatory cytokines (IL-1, IL-6, IL-17, and TNF- $\alpha$ ) (70). Similarly, in models of skin inflammation, S100A7 is produced in response to these cytokines (26). S100A7 is proposed as a novel biomarker for Alzheimer's disease; its concentration in the cerebrospinal fluid and expression in the brain are increased with increasing severity of disease (51). It has an important antibacterial action in skin both directly through a porin-like action on bacterial cell walls and indirectly through stimulation of the innate immune response. S100A7 induces neutrophil chemotaxis to sites of infection and at higher concentration stimulates them to degranulate, produce reactive oxygen species, and release proinflammatory cytokines (IL-6, IL-8, TNF- $\alpha$ , CCL3, CCL4, and CCL20) (75).

The effector cells of the innate immune system (neutrophils, macrophages, and natural killer cells) are found in abundance in the conjunctiva of children with active trachomatous inflammation and in adults with trachomatous scarring and inflammation (22). It appears likely that, in established trachomatous scarring, neutrophil chemotaxis is driven by CXCL5, S100A7, and IL-1 $\beta$ . Animal models of *C. trachomatis* infection indicate

that the greater the neutrophil infiltrate found in acute inflammation the more likely scarring complications are to develop (13, 54). Neutrophils respond to infection in a nonspecific manner, often damaging uninfected tissue. They release a range of proinflammatory chemokines/cytokines, augmenting the inflammatory response, produce reactive oxygen species and degranulate releasing a variety of molecules, such as MMP9, which can cause tissue damage. If this inflammatory response is sustained, extensive tissue damage is followed by aberrant epithelial repair in the form of scar tissue.

The microarray experiments identified several other markers suggestive of epithelial cell involvement in an innate immune response, including defensin  $\beta$ 4 and PLUNC. These are typically nonspecific responses to bacterial infection. Serum amyloid A1 (SAA1) is an acute-phase protein, deposited at sites of inflammation. Amyloid deposition has previously been demonstrated in conjunctival biopsy tissue from individuals with trachomatous scarring (27).

**Adaptive immune responses in scarring trachoma.** The resolution of *C. trachomatis* infection is thought to require an IFN- $\gamma$ -dependent T<sub>H</sub>1 cell-mediated immune response. A range of data from animal models and human studies support this conclusion (5). Nude mice cannot control *C. trachomatis* genital tract infection (55); however, this function can be restored by adoptive transfer of *C. trachomatis*-specific CD4<sup>+</sup> or CD8<sup>+</sup> lymphocytes (53). Murine studies indicate the importance of IFN- $\gamma$  in this response (43). We have previously reported increased IFN- $\gamma$  expression in children with active *C. trachomatis* infection, but not in those with signs of active disease in the absence of *C. trachomatis* infection (9). IFN- $\gamma$  is thought to mediate its action through various mechanisms, including the production of nitric oxide free radicals by iNOS (*NOS2A*) and intracellular tryptophan depletion through the action of IDO (*INDO*). In our study of conjunctival scarring, we did not find differences in the expression of IFN- $\gamma$  between cases and controls by quantitative RT-PCR. However, there was some limited indirect evidence of a T<sub>H</sub>1-type response associated with scarring, in that there was increased expression of *INDO* and *NOS2A*. In addition, *DUOX2* was also elevated in cases; this enzyme is found on epithelial cell surfaces and produces reactive oxygen species in response to T<sub>H</sub>1 stimulation.

There is more uncertainty about the role of T<sub>H</sub>2-type responses in chlamydial infection and trachoma. Earlier studies in populations where trachoma is endemic found that people with established scarring (compared to unscarred controls) had higher serum anti-*C. trachomatis* IgG titers and, when their peripheral blood mononuclear cells were stimulated with *C. trachomatis* antigens, these individuals had weaker proliferation responses and expressed IL-4 more frequently (28, 29). These observations were thought to be consistent with the hypothesis that an adverse scarred outcome is associated with a T<sub>H</sub>2-type response. However, it was unclear whether this association simply reflected a weaker T<sub>H</sub>1 response to infection, which was therefore more severe and/or prolonged, or whether T<sub>H</sub>2 responses directly promoted scarring and blunted T<sub>H</sub>1 efficacy.

Recently, there has been considerable interest in the role of IL-13 in fibrosis in a range of disease processes (73). This T<sub>H</sub>2 cytokine is thought to promote fibrosis through several mech-

anisms including the direct stimulation of fibroblasts and the “alternative activation” of macrophages to produce arginase 1 (*ARG1*), which is important in the production of collagen. In contrast, “classically activated” macrophages produce iNOS (*NOS2A*) in response to  $T_H1$ /IFN- $\gamma$  stimulation. This opposes the profibrotic action of IL-13.

We did not find any evidence of activation of  $T_H2$  pathways in the microarray experiments. In addition, by quantitative RT-PCR, the expression of IL-13 was reduced, and the expression of *IL13RA2* (the soluble decoy receptor antagonist) was increased. The functional effect of this decreased ratio of *IL13/IL13RA2* is consistent with the  $T_H1$ -type inflammatory environment evident in cases.

**Tissue remodeling and fibrosis.** Normal tissue structure is maintained through the “dynamic equilibrium” of various cellular processes, which build up or break down the ECM. A change in the relative activity of these processes, in disease, can lead to the accumulation of scar tissue. The development of conjunctival scar tissue in trachoma is poorly understood; it is possible that several different fibrogenic pathways contribute. In the microarray analysis of gene expression in scarred conjunctiva we found evidence of increased expression of several factors that could plausibly have roles in tissue remodeling (*MMP7*, *MMP9*, *MMP12*, *HAS*, *SPARCL*, and *CEACAM* genes) and enrichment of fibrogenic pathways (TGF/WNT).

The matrix metalloproteinases are a family of complex enzymes, which are involved in a wide range of cellular processes, including the regulation of the ECM, cytokine regulation, innate immunity, and development. MMP-7 (matrilysin) had the largest fold increase in trichiasis cases. This is consistent with findings from The Gambia, where MMP-7 was found to be upregulated in TT cases (30). MMP-7 is constitutively expressed in respiratory and other epithelial cells (20). Expression is increased in damaged and bacterially infected tissue. It seems to have an important role in innate immunity, through the activation of various components ( $\alpha$  and  $\beta$  defensins) and the recruitment of neutrophils. (7, 38) In addition, it regulates epithelial wound healing; MMP-7 activates MMP-9 and degrades collagen-1, collagen-4, laminin, and fibronectin. MMP-7 is an important downstream gene product of signaling in the WNT pathway.

*MMP9* expression was increased in cases, particularly in the presence of inflammation. This is consistent with earlier studies in both active and scarring trachoma, in which expression levels correlated with the clinical inflammatory score (9, 10). Immunohistochemistry indicates that, in children with active trachoma, MMP-9 is found in macrophages and neutrophils (21). We have previously described an association between a coding polymorphism in *MMP9* and reduced risk of scarring (44). In a mouse model of chlamydial genital tract infection, MMP-9-knockout animals had a reduced risk of scarring sequelae (33). Together, these observations suggest a role for MMP-9 in the pathogenesis of trachoma. A major MMP-9 function is the degradation of type IV collagen present in the basement membrane that disrupts the epithelium and facilitates the migration of cells. This is thought to be an initiating event in epithelial-mesenchymal transition, a process whereby epithelial cells migrate from the surface into the stroma (36). These cells are then thought to be able to take on a fibroblast phenotype and contribute to fibrosis. It is currently unknown

whether in trachoma the epithelium is a major source of fibroblasts. MMP-9 may also contribute to the development and maintenance of inflammation. Collagen fragments are both chemotactic and proinflammatory to monocytes and may linger for some time promoting a chronic inflammatory response (49).

*MMP12* (macrophage metalloelastase) expression was increased to a similar extent in cases with or without inflammation. This is consistent with results from a murine model of chlamydial genital infection, which showed a modest increase in expression (54). MMP-12 is mainly produced by macrophages. It degrades elastin and may be proinflammatory (47). It is prominent in respiratory tract disease such as emphysema, where destruction of elastin is important in the pathology. It is possible that in scarring trachoma MMP-12 is important in the degradation of the ECM and the promotion of inflammation.

The cytokine TGF- $\beta$  is known to be important in many scarring diseases. However, evaluation of its role in trachoma has remained elusive, partly because of its complex posttranscriptional regulation. Previously, we found no variation in the expression of *TGF $\beta$ 2* (the dominant conjunctival isoform) between individuals with active trachoma, individuals with chlamydial infection, or control subjects (9). Microarray analysis can provide some insight into the possible activity of TGF- $\beta$  by examining downstream pathways. In the present study, individuals with trichiasis and inflammation demonstrated enrichment of the TGF- $\beta$ /WNT pathway. We subsequently confirmed, by quantitative RT-PCR, increased expression of two downstream genes in the TGF- $\beta$ /WNT pathway, *NOS2A* and *MMP-7*, which have been found in other scarring disease processes (68). These observations are consistent with trachomatous scarring being driven at least in part by TGF- $\beta$ , although they do not provide direct since as other factors may also increase their expression.

**Limitations.** Microarray analysis of the transcriptome is a very powerful technique to simultaneously examine the transcriptional activity of the genome in specific tissues. However, describing the relative abundance of a transcript is only one level of a complex biological process. Inferences about the activity of some transcripts and target genes, such as *TGF $\beta$* , which is central to many fibrotic processes, cannot be easily investigated solely by this approach. Although we sampled in a noninvasive manner from the surface, this biases the resulting gene expression profile in favor of cells closer to the conjunctival surface. However, our recent studies of *in vitro* confocal microscopy indicate that most of the inflammatory cell activity in individuals with scarring is superficial (31). Azithromycin mass treatment had been distributed in virtually all districts where the cases and controls lived. Although azithromycin has a mild anti-inflammatory effect, this is probably relatively short-lived, and we presume that in a community treatment campaign cases and controls were equally likely to have received treatment.

Due to the severe nature of endemic trachoma in this region of Ethiopia, it is unusual to find older adults who do not have any conjunctival scarring. In order to meet the various matching criteria for the controls, we included individuals that had mild scarring, as well as controls with no scarring. However, we found only very limited evidence of any difference in gene expression between controls without scarring and those with

mild changes. This slight narrowing of the clinical distinction between cases and controls would, if anything, tend to lead to an underestimate in the size and strength of the effects measured.

**Conclusions.** Our findings suggest that the epithelium is not a passive bystander in cicatricial trachoma. Several proinflammatory molecules probably arise from the epithelium (IL-1B, CXCL5, and S100A7), leading to persistent recruitment of inflammatory cells into the conjunctiva, even in the absence of clinically visible inflammation. Various factors that are plausibly involved in the production of scar tissue were also detected. The driving force behind the responses at this stage of disease is not apparent. Current or recent *C. trachomatis* infection might have been expected to be associated with the inflammatory responses. However, the prevalence of *C. trachomatis* was negligible, probably reflecting the effectiveness of recent mass antibiotic treatment campaigns. Other bacteria and environmental factors could also promote inflammation in this previously damaged tissue. Longitudinal studies are needed to investigate which etiological factors and pathways are associated with progressive scarring and whether simply controlling chlamydial infection will halt progression in people with established cicatricial disease.

#### ACKNOWLEDGMENTS

This study was supported by a grant from The Wellcome Trust (080741/Z/06/Z), with additional support for fieldwork expenses from the Band Aid Foundation. The trachoma control program in Amhara Regional State is supported by the Amhara Regional Health Bureau and the Lions-Carter Center SightFirst Initiative.

#### REFERENCES

- Al-Rajhi, A. A., A. Hidayat, A. Nasr, and M. al-Faran. 1993. The histopathology and the mechanism of entropion in patients with trachoma. *Ophthalmology* **100**:1293–1296.
- Bas, S., L. Neff, M. Vuillet, U. Spenato, T. Seya, M. Matsumoto, and C. Gabay. 2008. The proinflammatory cytokine response to *Chlamydia trachomatis* elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. *J. Immunol.* **180**:1158–1168.
- Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc.* **57**: 289–300.
- Blodi, B. A., K. A. Byrne, and K. F. Tabbara. 1988. Goblet cell population among patients with inactive trachoma. *Int. Ophthalmol.* **12**:41–45.
- Brunham, R. C., and J. Rey-Ladino. 2005. Immunology of *Chlamydia* infection: implications for a *Chlamydia trachomatis* vaccine. *Nat. Rev. Immunol.* **5**:149–161.
- Bulut, Y., K. Shimada, M. H. Wong, S. Chen, P. Gray, R. Alsabeh, T. M. Doherty, T. R. Crother, and M. Arditi. 2009. Chlamydial heat shock protein 60 induces acute pulmonary inflammation in mice via the Toll-like receptor 4- and MyD88-dependent pathway. *Infect. Immun.* **77**:2683–2690.
- Burke, B. 2004. The role of matrix metalloproteinase 7 in innate immunity. *Immunobiology* **209**:51–56.
- Burton, M. J., R. A. Adegbola, F. Kinteh, U. N. Ikumapayi, A. Foster, D. C. Mabey, and R. L. Bailey. 2007. Bacterial infection and trachoma in The Gambia: a case control study. *Invest. Ophthalmol. Vis. Sci.* **48**:4440–4444.
- Burton, M. J., R. L. Bailey, D. Jeffries, D. C. Mabey, and M. J. Holland. 2004. Cytokine and fibrogenic gene expression in the conjunctivas of subjects from a Gambian community where trachoma is endemic. *Infect. Immun.* **72**:7352–7356.
- Burton, M. J., R. L. Bailey, D. Jeffries, S. N. Rajak, R. A. Adegbola, A. Sillah, D. C. Mabey, and M. J. Holland. 2010. Conjunctival expression of matrix metalloproteinase and proinflammatory cytokine genes after trichiasis surgery. *Invest. Ophthalmol. Vis. Sci.* **51**:3583–3590.
- Burton, M. J., M. J. Holland, N. Faal, E. A. Aryee, N. D. Alexander, M. Bah, H. Faal, S. K. West, A. Foster, G. J. Johnson, D. C. Mabey, and R. L. Bailey. 2003. Which members of a community need antibiotics to control trachoma? Conjunctival *Chlamydia trachomatis* infection load in Gambian villages. *Invest. Ophthalmol. Vis. Sci.* **44**:4215–4222.
- Burton, M. J., F. Kinteh, O. Jallow, A. Sillah, M. Bah, M. Faye, E. A. Aryee, U. N. Ikumapayi, N. D. Alexander, R. A. Adegbola, H. Faal, D. C. Mabey, A. Foster, G. J. Johnson, and R. L. Bailey. 2005. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. *Br. J. Ophthalmol.* **89**:1282–1288.
- Darville, T., C. W. Andrews, Jr., J. D. Sikes, P. L. Fraley, and R. G. Rank. 2001. Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection. *Infect. Immun.* **69**:3556–3561.
- Darville, T., J. M. O'Neill, C. W. Andrews, Jr., U. M. Nagarajan, L. Stahl, and D. M. Ojcius. 2003. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. *J. Immunol.* **171**:6187–6197.
- Dawson, C. R., B. R. Jones, and M. L. Tarizzo. 1981. Guide to trachoma control. World Health Organization, Geneva, Switzerland.
- Dawson, C. R., R. Marx, T. Daghfous, R. Juster, and J. Schachter. 1990. What clinical signs are critical in evaluating the intervention in trachoma?, p. 271–278. *In* W. R. Bowie (ed.), *Chlamydial infections*. Cambridge University Press, Cambridge, United Kingdom.
- De Paiva, C. S., A. L. Villarreal, R. M. Corrales, H. T. Rahman, V. Y. Chang, W. J. Farley, M. E. Stern, J. Y. Niederkorn, D. Q. Li, and S. C. Pflugfelder. 2007. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. *Invest. Ophthalmol. Vis. Sci.* **48**:2553–2560.
- Dennis, G., Jr., B. T. Sherman, D. A. Hosack, J. Yang, W. Gao, H. C. Lane, and R. A. Lempicki. 2003. DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol.* **4**:3.
- Du, P., W. A. Kibbe, and S. M. Lin. 2008. Lumi: a pipeline for processing Illumina microarray. *Bioinformatics* **24**:1547–1548.
- Dunsmore, S. E., U. K. Saarialho-Kere, J. D. Roby, C. L. Wilson, L. M. Matrisian, H. G. Welgus, and W. C. Parks. 1998. Matrilysin expression and function in airway epithelium. *J. Clin. Invest.* **102**:1321–1331.
- El-Asrar, A. M., K. Geboes, S. A. Al-Kharashi, A. A. Al-Mosallam, L. Missotten, L. Paemen, and G. Opedenaker. 2000. Expression of gelatinase B in trachomatous conjunctivitis. *Br. J. Ophthalmol.* **84**:85–91.
- El-Asrar, A. M., K. Geboes, K. F. Tabbara, S. A. Al-Kharashi, L. Missotten, and V. Desmet. 1998. Immunopathogenesis of conjunctival scarring in trachoma. *Eye* **12**:453–460.
- El-Asrar, A. M., J. J. Van den Oord, K. Geboes, L. Missotten, M. H. Emarah, and V. Desmet. 1989. Immunopathology of trachomatous conjunctivitis. *Br. J. Ophthalmol.* **73**:276–282.
- Gielsing, R. G., K. Wallace, and Y. P. Han. 2009. Interleukin-1 participates in the progression from liver injury to fibrosis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **296**:G1324–G1331.
- Grayston, J. T., S. P. Wang, R. L. Woolridge, and E. R. Alexander. 1964. Prevention of trachoma with vaccine. *Arch. Environ. Health* **89**:518–526.
- Guilleteau, K., I. Paris, N. Pedretti, K. Boniface, F. Juchaux, V. Huguier, G. Guillet, F. X. Bernard, J. C. Lecron, and F. Morel. 2010. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1 $\alpha$ , and TNF- $\alpha$  recapitulates some features of psoriasis. *J. Immunol.* **184**:5263–5270.
- Guzey, M., I. Ozardali, E. Basar, G. Aslan, A. Satici, and S. Karade. 2000. A survey of trachoma: the histopathology and the mechanism of progressive cicatrization of eyelid tissues. *Ophthalmologica* **214**:277–284.
- Holland, M. J., R. L. Bailey, D. J. Conway, F. Culley, G. Miranpuri, G. I. Byrne, H. C. Whittle, and D. C. Mabey. 1996. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of *Chlamydia trachomatis* in subjects with severe trachomatous scarring. *Clin. Exp. Immunol.* **105**:429–435.
- Holland, M. J., R. L. Bailey, L. J. Hayes, H. C. Whittle, and D. C. Mabey. 1993. Conjunctival scarring in trachoma is associated with depressed cell-mediated immune responses to chlamydial antigens. *J. Infect. Dis.* **168**:1528–1531.
- Holland, M. J., D. Jeffries, M. Pattison, G. Korr, A. Gall, H. Joof, A. Manjang, M. J. Burton, D. C. Mabey, and R. L. Bailey. 2010. Conjunctival gene expression profiling using pathway focused arrays reveals increased matrix metalloproteinase-7 (matrilysin) transcription in trachomatous trichiasis. *Invest. Ophthalmol. Vis. Sci.* **51**:3893–3902.
- Hu, V. H., P. Massae, H. A. Weiss, I. A. Cree, P. Courtright, D. C. Mabey, R. L. Bailey, and M. J. Burton. *In vivo* confocal microscopy of trachoma in relation to normal tarsal conjunctiva. *Ophthalmology*, in press.
- Huang, d. W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**:44–57.
- Intiaz, M. T., J. T. Distelhorst, J. H. Schripsema, I. M. Sigar, J. N. Kasimos, S. R. Lacy, and K. H. Ramsey. 2007. A role for matrix metalloproteinase-9 in pathogenesis of urogenital *Chlamydia* muridarum infection in mice. *Microbes Infect.* **9**:1561–1566.
- Jeyaseelan, S., R. Manzer, S. K. Young, M. Yamamoto, S. Akira, R. J. Mason, and G. S. Worthen. 2005. Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium. *Am. J. Respir. Cell Mol. Biol.* **32**:531–539.
- Joyee, A. G., and X. Yang. 2008. Role of Toll-like receptors in immune responses to chlamydial infections. *Curr. Pharm. Des.* **14**:593–600.
- Kalluri, R., and R. A. Weinberg. 2009. The basics of epithelial-mesenchymal transition. *J. Clin. Invest.* **119**:1420–1428.

37. Karimi, O., S. Ouburg, H. J. de Vries, A. S. Pena, J. Pleijster, J. A. Land, and S. A. Morre. 2009. TLR2 haplotypes in the susceptibility to and severity of *Chlamydia trachomatis* infections in Dutch women. *Drugs Today* **45**(Suppl. B):67–74.
38. Li, Q., P. W. Park, C. L. Wilson, and W. C. Parks. 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. *Cell* **111**:635–646.
39. Li, S., K. Nikulina, J. DeVoss, A. J. Wu, E. C. Strauss, M. S. Anderson, and N. A. McNamara. 2008. Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease. *Invest. Ophthalmol. Vis. Sci.* **49**:34–41.
40. Lin, S. M., P. Du, W. Huber, and W. A. Kibbe. 2008. Model-based variance-stabilizing transformation for Illumina microarray data. *Nucleic Acids Res.* **36**:e11.
41. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* **25**:402–408.
42. Mantelli, F., and P. Argueso. 2008. Functions of ocular surface mucins in health and disease. *Curr. Opin. Allergy Clin. Immunol.* **8**:477–483.
43. Morrison, R. P., and H. D. Caldwell. 2002. Immunity to murine chlamydial genital infection. *Infect. Immun.* **70**:2741–2751.
44. Natividad, A., G. Cooke, M. J. Holland, M. J. Burton, H. M. Joof, K. Rockett, D. P. Kwiatkowski, D. C. Mabey, and R. L. Bailey. 2006. A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular *Chlamydia trachomatis* infection. *BMC Med. Genet.* **7**:40:40.
45. Natividad, A., N. Hanchard, M. J. Holland, O. S. Mahdi, M. Diakite, K. Rockett, O. Jallow, H. M. Joof, D. P. Kwiatkowski, D. C. Mabey, and R. L. Bailey. 2007. Genetic variation at the TNF locus and the risk of severe sequelae of ocular *Chlamydia trachomatis* infection in Gambians. *Genes Immun.* **8**:288–295.
46. Nedeau, A. E., R. J. Bauer, K. Gallagher, H. Chen, Z. J. Liu, and O. C. Velazquez. 2008. A CXCL5- and bFGF-dependent effect of PDGF-B-activated fibroblasts in promoting trafficking and differentiation of bone marrow-derived mesenchymal stem cells. *Exp. Cell Res.* **314**:2176–2186.
47. Nenán, S., E. Boichot, V. Lagente, and C. P. Bertrand. 2005. Macrophage elastase (MMP-12): a proinflammatory mediator? *Mem. Inst. Oswaldo Cruz* **100**(Suppl. 1):167–172.
48. O'Connell, C. M., I. A. Ionova, A. J. Quayle, A. Visintin, and R. R. Ingalls. 2006. Localization of TLR2 and MyD88 to *Chlamydia trachomatis* inclusions: evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen. *J. Biol. Chem.* **281**:1652–1659.
49. Opendakker, G., P. E. Van den Steen, B. Dubois, I. Nelissen, E. Van Coillie, S. Masure, P. Proost, and J. Van Damme. 2001. Gelatinase B functions as regulator and effector in leukocyte biology. *J. Leukoc. Biol.* **69**:851–859.
50. Prantner, D., T. Darville, J. D. Sikes, C. W. Andrews, Jr., H. Brade, R. G. Rank, and U. M. Nagarajan. 2009. Critical role for IL-1 $\beta$  during *Chlamydia muridarum* genital infection and bacterial replication-independent secretion of IL-1 $\beta$  in mouse macrophages. *Infect. Immun.* **77**:5334–5346.
51. Qin, W., L. Ho, J. Wang, E. Peskind, and G. M. Pasinetti. 2009. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. *PLoS One* **4**:e4183.
52. Ramsey, K. H. 2006. Alternative mechanisms of pathogenesis, p. 435–473. *In* P. M. Bavoil and P. B. Wyrick (ed.), *Chlamydia: genomics and pathogenesis*. Horizon Bioscience, Wymondham, United Kingdom.
53. Ramsey, K. H., and R. G. Rank. 1991. Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. *Infect. Immun.* **59**:925–931.
54. Ramsey, K. H., I. M. Sigar, J. H. Schripsema, N. Shaba, and K. P. Cohoon. 2005. Expression of matrix metalloproteinases subsequent to urogenital *Chlamydia muridarum* infection of mice. *Infect. Immun.* **73**:6962–6973.
55. Rank, R. G., L. S. Soderberg, and A. L. Barron. 1985. Chronic chlamydial genital infection in congenitally athymic nude mice. *Infect. Immun.* **48**:847–849.
56. Rasmussen, S. J., L. Eckmann, A. J. Quayle, L. Shen, Y. X. Zhang, D. J. Anderson, J. Fierer, R. S. Stephens, and M. F. Kagnoff. 1997. Secretion of proinflammatory cytokines by epithelial cells in response to *Chlamydia* infection suggests a central role for epithelial cells in chlamydial pathogenesis. *J. Clin. Invest.* **99**:77–87.
57. Resnikoff, S., D. Pascolini, D. Etya'ale, I. Kocur, R. Pararajasegaram, G. P. Pokharel, and S. P. Mariotti. 2004. Global data on visual impairment in the year 2002. *Bull. World Health Organ.* **82**:844–851.
58. Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. *Nat. Rev. Immunol.* **10**:89–102.
59. Skwor, T. A., B. Atik, R. P. Kandel, H. K. Adhikari, B. Sharma, and D. Dean. 2008. Role of secreted conjunctival mucosal cytokine and chemokine proteins in different stages of trachomatous disease. *PLoS Negl. Trop. Dis.* **2**:e264.
60. Smyth, G. K. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* **3**:Article 3.
61. Solomon, A. W., M. J. Holland, N. D. Alexander, P. A. Massae, A. Aguirre, A. Natividad-Sancho, S. Molina, S. Safari, J. F. Shao, P. Courtright, R. W. Peeling, S. K. West, R. L. Bailey, A. Foster, and D. C. Mabey. 2004. Mass treatment with single-dose azithromycin for trachoma. *N. Engl. J. Med.* **351**:1962–1971.
62. Solomon, A. W., M. J. Holland, M. J. Burton, S. K. West, N. D. Alexander, A. Aguirre, P. A. Massae, H. Mkocho, B. Munoz, G. J. Johnson, R. W. Peeling, R. L. Bailey, A. Foster, and D. C. Mabey. 2003. Strategies for control of trachoma: observational study with quantitative PCR. *Lancet* **362**:198–204.
63. Sowa, S., J. Sowa, L. H. Collier, and W. A. Blyth. 1969. Trachoma vaccine field trials in The Gambia. *J. Hyg. (Lond.)* **67**:699–717.
64. Stamm, W. E. 2003. Rationale for a Vaccine: Proceedings of the *Chlamydia* Vaccine Development Colloquium, The Albert B. Sabin Vaccine Institute, Washington, DC.
65. Stutz, A., D. T. Golenbock, and E. Latz. 2009. Inflammasomes: too big to miss. *J. Clin. Invest.* **119**:3502–3511.
66. Taylor, H. R., S. L. Johnson, J. Schachter, H. D. Caldwell, and R. A. Prendergast. 1987. Pathogenesis of trachoma: the stimulus for inflammation. *J. Immunol.* **138**:3023–3027.
67. Verdoni, A. M., R. S. Smith, A. Ikeda, and S. Ikeda. 2008. Defects in actin dynamics lead to an autoinflammatory condition through the upregulation of CXCL5. *PLoS One* **3**:e2701.
68. von Toerne, C., C. Schmidt, J. Adams, E. Kiss, J. Bedke, S. Porubsky, N. Gretz, M. T. Lindenmeyer, C. D. Cohen, H. J. Grone, and P. J. Nelson. 2009. Wnt pathway regulation in chronic renal allograft damage. *Am. J. Transplant.* **9**:2223–2239.
69. Wang, S. P., J. T. Grayston, and E. R. Alexander. 1967. Trachoma vaccine studies in monkeys. *Am. J. Ophthalmol.* **63**(Suppl.):30.
70. West, N. R., and P. H. Watson. 2010. S100A7 (psoriasis) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. *Oncogene* **29**:2083–2092.
71. West, S. K., B. Munoz, H. Mkocho, Y. H. Hsieh, and M. C. Lynch. 2001. Progression of active trachoma to scarring in a cohort of Tanzanian children. *Ophthalmic Epidemiol.* **8**:137–144.
72. West, S. K., E. S. West, W. Alemayehu, M. Melese, B. Munoz, A. Imeru, A. Worku, C. Gaydos, C. L. Meinert, and T. Quinn. 2006. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. *Arch. Ophthalmol.* **124**:309–314.
73. Wynn, T. A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. *Nat. Rev. Immunol.* **4**:583–594.
74. Wyrick, P. B., S. T. Knight, T. R. Paul, R. G. Rank, and C. S. Barbier. 1999. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. *J. Infect. Dis.* **179**:954–966.
75. Zheng, Y., F. Niyonsaba, H. Ushio, S. Ikeda, I. Nagaoka, K. Okumura, and H. Ogawa. 2008. Microbicidal protein psoriasisin is a multifunctional modulator of neutrophil activation. *Immunology* **124**:357–367.